STATE OF WISCONSIN v. INDIVIOR INC.

District Court, E.D. Pennsylvania·Decided September 2, 2021·No. 2:16-cv-05073·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA __________________________________________ IN RE SUBOXONE (BUPRENORPHINE : MDL NO. 2445 HYDROCHLORIDE AND NALOXONE) : 13-MD-2445 ANTITRUST LITIGATION : : THIS DOCUMENT RELATES TO:, : : Wisconsin, et al. v. Indivior Inc. et al. : Case No. 16-cv-5073 : __________________________________________: STATE OF WISCONSIN : By Attorney General Brad D. Schimel, et al. : : CIV. A. NO. 16-5073 Plaintiffs, : v. : : INDIVIOR INC. f/k/a RECKITT BENCKISER : PHARMACEUTICALS, INC., et al. : : Defendants. : __________________________________________:

Goldberg, J. September 2, 2021 MEMORANDUM Currently before me in this multi-district antitrust case is the End-Payor Plaintiffs’ (“EPPs”) Motion for Approval of Notice to prospective class members, which Defendant opposes. For the following reasons, I will deny the EPPs’ Motion without prejudice and allow for an Amended Motion to Approve the Form and Manner of Notice to be filed within thirty days. I. RELEVANT FACTUAL BACKGROUND1 Defendant Indivior, Inc. (“Defendant”) manufactures Suboxone, a drug commonly used to combat opioid addiction. Suboxone previously came in tablet form, but in 2010, citing safety

1 Rather than re-stating the complicated regulatory background and factual basis of this case, I incorporate by reference the history set forth in my prior decision certifying a class for both the DPPs and EPPs. In re Suboxone Antitrust Litig., 421 F. Supp. 3d 12 (E.D. Pa. 2019), aff’d, 967 F.3d 264 (3d Cir. 2020). concerns, Defendant effectuated a change in the administration of this drug, switching from tablet to sublingual film. Various purchasers/consumers of Suboxone claimed that this switch was anticompetitive and solely designed to maintain Defendant’s market exclusivity—a scheme known as a “product hop.” These claims have resulted in multi-district, antitrust litigation before this Court. On September 27, 2019, I certified a class of End Payor Plaintiffs pursuant to Federal Rule of Civil Procedure 23(c)(4) on six distinct issues: 1. Whether Defendant engaged in anticompetitive and deceptive conduct; 2. Whether Defendant willfully maintained monopoly power through such conduct; 3. Whether Defendant had a specific intent to monopolize; 4. Whether Defendant had a dangerous probability of achieving monopoly power; 5. Whether Defendant has offered a non-pretextual pro- competitive justification that could not have have been obtained through less restrictive means, and if so; 6. Whether the anticompetitive effects of Defendant’s conduct outweigh their proffered procompetitive benefits, if any.

In re Suboxone Antitrust Litig., No. 13-md-2445, 2019 WL 4735520 (E.D. Pa. Sept. 27, 2019). The United States Court of Appeals for the Third Circuit affirmed this certification on July 28, 2020. In re Suboxone Antitrust Litig., 967 F.3d 264 (3d Cir. 2020). On March 8, 2021, the EPPs sought an order approving the form and manner of notice to the End Payor Class informing them of the pendency of this class action. Defendant opposed the EPPs’ Motion on the grounds of several alleged defects in the proposed form and manner of notice. II. DISCUSSION

The EPP class is comprised of two types of class members: (a) third-party payors, who are health and welfare plans or insurance companies that pay and/or reimburse for prescription drug purchases of their members, and (b) consumers, who are individuals who purchase prescription drugs. As to the third-party payors, the EPPs propose to send direct notice via U.S. First Class mail to reasonably identifiable third-party payors, including entities such as insurance companies, health maintenance organizations, and self-insured entities. That direct notice will be supplemented with a digital ad program on Think.Advisor.com/life-health, which will be designed to reach unidentified third-party payors. As to the consumers, the EPPs propose to utilize a publication campaign comprised of digital media and earned media. The EPPs plan to place digital banner, text and/or newsfeed ads through Google Display Networks and Google AdWords, social media platforms Facebook and Instagram, and specifically targeted medical networks including websites like WebMD.com. This digital network and social media campaign will run for thirty days and will be

monitored to ensure success and optimize the number of impressions delivered across each platform to achieve maximum engagement and efficiency. The EPPs also propose to issue a news release via PR Newsire’s US1 and Multi-cultural Newsline distribution lists, which will be distributed to the news desks of approximately 10,000 newsrooms. The EPPs have designated A.B. Data, Ltd. as the notice administrator tasked with effectuating notice of this class action lawsuit to both the third-party payors and the consumer class members. Defendant opposes the EPPs’ Motion, noting three alleged defects: (1) the notice plan fails to provide individualized notice to consumers; (2) the notice plan is deficient as to the third-party payors; and (3) the short- and long-form notices require correction before distribution. A. Notice to Consumers

Defendant first argues that the proposed notice plan as to the consumer portion of the EPP class violates the dictates of Federal Rule of Civil Procedure 23 and the Due Process Clause. Defendant asserts that in their motion for class certification, the EPPs originally averred that they had a sufficient method to ascertain the identities of almost all class members through the use of subpoenas directed to the top six pharmacy benefit managers, the ten largest third-party payors, and the top ten chain store pharmacies. Yet, according to Defendant, in the seventeen months that has elapsed since certification of the EPP class, EPP counsel has failed to implement any plan for specifically identifying any other class members other than the named Plaintiffs. Instead, the EPPs now propose to notify the consumer portion of the class solely by publication rather than by individual notice. Defendant asserts that this notification plan is inconsistent with Rule 23(c)(2)’s command that “the court must direct to class members the best notice that is practicable under the circumstances, including individual notice to all members who can be identified through reasonable effort.” Fed. R. Civ. P. 23(c)(2)(B). “In the class action context, the district court obtains personal jurisdiction over the

absentee class members by providing proper notice of the impending class action and providing the absentees with the opportunity to be heard or the opportunity to exclude themselves from the class.” In re Prudential Ins. Co. of Am. Sales Practices Litig., 148 F.3d 283, 306 (3d Cir. 1998) (citing Phillips Petroleum Co. v. Shutts, 472 U.S. 797, 811–12 (1985)). “The combination of reasonable notice, the opportunity to be heard and the opportunity to withdraw from the class satisfy the due process requirements of the Fifth Amendment.” Id. The “‘mandatory notice [of Federal Rule of Civil Procedure 23(c)(2)] . . .

Free access — add to your briefcase to read the full text and ask questions with AI

STATE OF WISCONSIN v. INDIVIOR INC., (E.D. Pa. 2021).

STATE OF WISCONSIN v. INDIVIOR INC. (STATE OF WISCONSIN v. INDIVIOR INC.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
Eisen v. Carlisle & Jacquelin
417 U.S. 156 (Supreme Court, 1974)
Phillips Petroleum Co. v. Shutts
472 U.S. 797 (Supreme Court, 1985)
Judy Larson v. AT&T Mobility LLC
687 F.3d 109 (Third Circuit, 2012)
Crystal Byrd v. Aaron's Inc
784 F.3d 154 (Third Circuit, 2015)
In re: Suboxone Antitrust v.
967 F.3d 264 (Third Circuit, 2020)
Hall v. Best Buy Co.
274 F.R.D. 154 (E.D. Pennsylvania, 2011)
Carlough v. Amchem Products, Inc.
158 F.R.D. 314 (E.D. Pennsylvania, 1993)